Daniel F. Sahm, PhD

VP Global Microbiology Services & Chief Scientific Officer
IHMA

Disclosure(s): Pfizer, Inc.: Advisor/Consultant

Poster(s):

• (P-1355) Trends in Carbapenemase and Co-carbapenemase Production among Enterobacterales in Latin America: SMART 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1506) In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-acquired Respiratory Tract Infections as a Part of the ATLAS Global Surveillance Program 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1507) In Vitro Activity of Ceftazidime-avibactam against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1508) In Vitro Activity of Aztreonam-avibactam against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1509) In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1510) In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2022 by Region
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1511) In Vitro Activity of Gepotidacin Against Molecularly Characterized Neisseria gonorrhoeae Isolates Exhibiting Reduced Susceptibility to Antibacterial Agents, 2018-2021
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1513) In Vitro Activity of Ceftaroline against Bacterial Pathogens from Pediatric Patients Collected During the ATLAS Global Surveillance Program in 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1514) Cefepime-taniborbactam Exhibits Limited Cross-resistance with Ceftazidime-avibactam and Ceftolozane-tazobactam against Carbapenem-nonsusceptible Enterobacterales and Multidrug-resistant Pseudomonas aeruginosa from the United States 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1518) Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam and Comparators Against Clinical MDR and DTR non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa Stratified by Patient Age and Hospital Ward: SMART United States 2020-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1519) Susceptibility of Clinical Non-Morganellaceae Enterobacterales Isolates from Bloodstream and Respiratory Tract Infections to Imipenem/Relebactam and Comparators: SMART United States 2020-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1520) Addition of Relebactam Increases Susceptibility to Imipenem Among Imipenem-Intermediate Pseudomonas aeruginosa: Asia/Pacific SMART 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1521) Susceptibility of Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) With and Without Carbapenemases to Cefepime-Taniborbactam and Comparators: GEARS Antimicrobial Surveillance Program, United States, 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT